Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Glioma Treatment Market from 2024 to 2025?

The market size for glioma treatment has seen significant growth over the past few years. The market, which was valued at $5.06 billion in 2024, is projected to increase to $5.39 billion in 2025, with a compound annual growth rate (CAGR) of 6.4%. This notable expansion in the previous period is attributed to such factors as an increase in glioma cases, progress in molecular comprehension, the development of conventional therapies, advancements in clinical trials and research, and enhancements in imaging and diagnostic procedures.

What Is the Projected Market Size of the Glioma Treatment Market?

The market for glioma treatment is projected to witness robust expansion in the upcoming years, escalating to a value of “$6.97 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. This projected surge during the estimated period could be due to the development of personalized treatments and the discovery of biomarkers, enhancements in immunotherapies, the integration of targeted treatments, the development of new therapeutic platforms, and collective research efforts. Prominent trends for this forecast period encompass agents that can penetrate the blood-brain barrier, monitoring through liquid biopsy, an emphasis on quality of life and supportive care, genetic and molecular subtyping, along with increased patient advocacy and participation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10689&type=smp

Who are the Major Competitors in the Glioma Treatment Market Outlook?

Major companies operating in the glioma treatment market include Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

What Is Fueling Growth in the Glioma Treatment Market?

The expansion of the glioma treatment market is being fueled by a rising interest in personalized medicine. This kind of healthcare strategy incorporates individual characteristics such as genetics, environmental factors, and lifestyle habits to increase the effectiveness and success of the treatment. This growing need is supported by various factors like advancements in genomics, a thirst for patient empowerment, and better treatment results. The discovery of biomarkers related to gliomas allows prediction of treatment responses and results, which facilitates the creation of personalized treatment strategies designed to meet the distinct properties of each patient. For example, as per the Personalized Medicine Coalition, a non-profit organization in the US, in February 2024 the FDA gave approval to 16 new personalized therapies for rare diseases in 2023, a noticeable increase from the six approvals in 2022. Consequently, the escalating demand for personalized medicine is propelling the growth of the glioma treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10689&type=smp

Which Glioma Treatment Market Segments Are Growing the Fastest?

The glioma treatment market covered in this report is segmented –

1) By Type: Low-Grade, High-Grade

2) By Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases

3) By Route Of Administration: Oral, Parenteral, Other Routes

4) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Drug Therapy, Other Treatments

5) By End-User: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Low-Grade: Astrocytoma, Oligodendroglioma, Mixed Glioma

2) By High-Grade: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma

Which Industry Trends Are Shaping the Future of the Glioma Treatment Market?

Product innovation is leading the way as a central trend in the glioma treatment market. Major businesses within this field are embracing new and inventive products to maintain their hold over the market. A notable example can be seen in June 2024, when Servier Pharmaceuticals, a pharmaceutical enterprise based in France, gained FDA approval for VORANIGO (vorasidenib) tablets – an extraordinary landmark as the debut targeted therapy for Grade 2 IDH-mutant glioma. Vorasidenib is a combined inhibitor targeting isocitrate dehydrogenase (IDH) 1 and 2 mutations, mutations often identified in gliomas. These mutations give rise to 2-hydroxyglutarate (2-HG), a metabolite that aids in tumor growth and survival. By targeting these enzymes, vorasidenib decreases 2-HG levels, ideally leading to a slow down in tumor progression.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Which Countries Are Leading the Glioma Treatment Market?

North America was the largest region in the glioma treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global glioma treatment market report during the forecast period. The regions covered in the glioma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10689

This Report Delivers Insight On:

1. How big is the glioma treatment market, and how is it changing globally?

2. Who are the major companies in the glioma treatment market, and how are they performing?

3. What are the key opportunities and risks in the glioma treatment market right now?

4. Which products or customer segments are growing the most in the glioma treatment market?

5. What factors are helping or slowing down the growth of the glioma treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model